FMS Short Interest Hits Year High as Parent Trims Stake

Short interest in FMS has climbed to its highest level in at least a year, rising 50% over the past month to 4.22 million shares, with the steepest jump arriving in the week of October 20 when the position grew 26% in five sessions. The surge coincides with Fresenius SE & Co. KGaA, the controlling parent, cutting its stake from 28.6% to 25.6% in a filing dated August 24, a disposal of roughly 16.6 million shares that represents one of the most significant ownership changes on the register in recent years.

The activist angle matters here. Fresenius SE filed a Schedule 13D/A, meaning it holds a formal activist designation on its own subsidiary's register. Its continued trimming, now for the third time since first filing in March 2025, has removed a price-support dynamic that many holders assumed was structural. That selldown has not gone unnoticed by short sellers: the week ending October 23 shows a step-change in the short position, jumping from 3.1 million to 4.2 million shares in a single week. Per the most recent FINRA settlement data, days to cover stand at 3.5, giving the position material weight against normal trading volume. Borrow availability remains loose at 442%, so adding to a short position is straightforward at current cost to borrow of 3.75%.

The analyst community has grown more cautious but remains largely sidelined rather than outright negative. Truist Securities trimmed its target to $24 from $25 on October 12, keeping a Hold rating. The stock closed Friday at $22.47, down 2.9% on the day, so it is already trading through that target. The most recent analyst note with a directional conviction call came from UBS in September 2025, a downgrade to Sell. There is no bellwether-firm upgrade in the recent record. The EV/EBITDA multiple of 4.3x and a price-to-book below 0.85 suggest the market is not pricing in a recovery, and the earnings yield ranks in the 93rd percentile across the ORTEX universe, reflecting how cheap the stock has become on a trailing basis. Forward earnings revisions tell the opposite story: the 12-month forward EPS estimate is tracking in the bottom fifth of the universe, with a 90-day momentum score of 33 out of 100.

Fresenius Medical Care has delivered negative first-day returns after each of its last three earnings releases, falling between 2.5% and 6.4% on the day of the print. The five-day reactions were similarly negative in each case, ranging from 2.5% to 5.5% lower. The November 3 release will test whether the parent's continued share disposal has removed a floor, and whether the jump in short interest reflects a well-founded read on the operational numbers or an overcrowded trade ahead of results where the valuation has already compressed significantly.